Vincenzo Di Noia
A5042730999- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- SARS-CoV-2 and COVID-19 Research
- Lung Cancer Research Studies
- COVID-19 and healthcare impacts
- Gastric Cancer Management and Outcomes
- Immunotherapy and Immune Responses
- Vaccine Coverage and Hesitancy
- Lung Cancer Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Neuroendocrine Tumor Research Advances
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Pleural and Pulmonary Diseases
- Occupational and environmental lung diseases
- Hepatocellular Carcinoma Treatment and Prognosis
- PI3K/AKT/mTOR signaling in cancer
- Gut microbiota and health
- Cancer Treatment and Pharmacology
- Gastrointestinal Tumor Research and Treatment
- Cancer Diagnosis and Treatment
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- COVID-19 Clinical Research Studies
- Medical Imaging and Pathology Studies
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2025
Università Cattolica del Sacro Cuore
2015-2021
Humanitas Gavazzeni
2020-2021
University of Foggia
2020-2021
Ospedali Riuniti di Foggia
2020-2021
Agostino Gemelli University Polyclinic
2017-2019
Background The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. Methods We present the analysis according to baseline body mass index (BMI) BMI variation a large cohort metastatic NSCLC with expression ≥50%, first line pembrolizumab. also evaluated control treated platinum-based...
To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated first-line immunotherapy.Baseline clinical prognostic factors, neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour expression level, lactate dehydrogenase (LDH) and their combination were investigated by a retrospective analysis 784 divided between statistically powered training (n = 201) validation 583) cohorts. Cut-offs explored receiver operating...
We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection.An evaluation was carried out among health care workers (HCW) vaccinated at Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by national campaign beginning 2021. Serum samples collected on day 1 just prior 21 second vaccination dose. Thereafter sera 28, 49, 84 168 days BNT162b2. Quantitative measurement IgG...
Abstract Background Improved outcome in tobacco smoking patients with non‐small cell lung cancer (NSCLC) following immunotherapy has previously been reported. However, little is known regarding this association during first‐line high PD‐L1 expression. In study we compared clinical outcomes according to the status of two large multicenter cohorts. Methods We (never smokers vs. current/former smokers) retrospective cohorts metastatic NSCLC patients, treated pembrolizumab and platinum‐based...
We assessed the immunogenicity and safety of BNT162b2 vaccine in a large cohort patients with cancer (CP).From March 1, 2021 to 20, 2021, this prospective study included 816 CP afferent our institution eligible for vaccination. A 274 health care workers (HCW) was used as age- sex-matched control group. administered two-dose regimen given 21 days apart. Blood samples analyze anti-Spike (S) IgG antibodies (Ab) were collected prevaccination [timepoint (TP) 0], at 3 weeks (TP1) 7 (TP2) after...
Aim: To evaluate gefitinib outcomes in EGFR-mutated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations, according to their sarcopenia status. Patients & methods: We retrospectively evaluated 33 with advanced NSCLC and mutations (exon 19 or 21), dividing them into sarcopenic patients, low skeletal muscle index ≤39 cm2/m2 for women ≤55 men, nonsarcopenic patients. Results: Sarcopenia does not affect response treatment mutated even if it is a bad prognostic indicator overall...
Aim: The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in EGFR-mutated non-small-cell lung cancer patients experiencing disease progression under TKIs could be a valid an option. Patients & methods: We included 131 during first-line TKI. In group A, received TKI beyond site(s) were irradiated; B, remained on alone progression; C stopped at first progression. Results: Median overall survival resulted longer A versus B (p < 0.0001). Group had trend toward second...
Abstract Background Identifying the patients who may benefit most from immune checkpoints inhibitors remains a great challenge for clinicians. Here we investigate on blood serum amyloid A (SAA) as biomarker of response to upfront pembrolizumab in with advanced non-small-cell lung cancer (NSCLC). Methods Patients PD-L1 ≥ 50% receiving (P cohort) and 0–49% treated chemotherapy (CT were evaluated SAA radiological at baseline every 9 weeks. Endpoints rate (RR) according RECIST1.1,...